慢性乙型肝炎临床治愈与肝脏CD4+ T细胞应答的启动和维持相关
研究利用年龄依赖性HBsAg清除或持续的小鼠模型及BeNEG-DO临床试验纵向血样,探讨慢性乙型肝炎HBsAg清除的免疫机制。发现成人小鼠肝脏HBV特异性CD4+ T细胞应答强并实现HBsAg清除,清除CD4+ T细胞可阻止清除,而清除CD8+ T细胞不影响。患者样本中HBsAg清除特征与小鼠模型重叠,提示增强CD4+ T细胞应答可能提高HBsAg清除率。
要点
- 肝脏HBV特异性CD4+ T细胞应答的启动和维持与HBsAg清除相关。
- 清除CD4+ T细胞可阻止HBsAg血清清除,而清除CD8+ T细胞不影响。
- 患者HBsAg清除特征与小鼠模型重叠,提示CD4+ T细胞靶向治疗潜力。
核心结论
- CD4+ T细胞活化在慢性乙型肝炎临床治愈中发挥作用,治疗性增强CD4+ T细胞应答可能提高HBsAg清除率。
研究设计与样本
- 使用年龄依赖性HBsAg清除或持续的小鼠模型,以及BeNEG-DO临床试验中停止核苷(酸)类似物治疗后出现HBsAg清除或HBsAg水平稳定保持的参与者的纵向外周血样本。
主要发现
- 年轻小鼠HBsAg清除失败,肝脏中启动和维持HBV特异性CD4+ T细胞应答的能力受损;成年小鼠表现出强HBV特异性CD4+ T细胞应答和HBsAg清除。
- 在成年小鼠中清除CD4+ T细胞可阻止HBsAg血清清除和肝细胞损伤,并破坏肝脏白细胞组织和HBV特异性CD8+ T细胞细胞毒性;清除CD8+ T细胞不改变HBsAg血清清除。
- 肝脏髓系细胞,特别是2型经典树突状细胞,指导CD4+ T细胞的启动和分化。
- 慢性乙型肝炎患者样本中HBsAg清除特征与小鼠模型重叠,包括辅助性T细胞1和细胞毒性CD4+ T细胞活化以及CD8+ T细胞效应功能增强。
临床怎么用
- 提示可通过治疗性增强CD4+ T细胞应答来提高慢性乙型肝炎患者的HBsAg清除率。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Chronic infection with hepatitis B virus (HBV) often leads to immune-mediated progressive liver injury and liver cancer. Seroclearance of the surface antigen (HBsAg) defines clinical cure and reduces disease-associated risks but rarely occurs. Here, we aimed to study the immune mechanisms of HBsAg clearance in chronic hepatitis B (CHB) using a mouse model of age-dependent HBsAg clearance and persistence and longitudinal peripheral blood samples from participants in the BeNEG-DO clinical trial who exhibited either HBsAg clearance or stable HBsAg level retention after stopping nucleos(t)ide analog therapy. Whereas HBsAg clearance in young mice failed and the ability to initiate and sustain HBV-specific CD4+ T cell responses in the liver was impaired, adult mice exhibited a robust HBV-specific CD4+ T cell response and HBsAg clearance. Depletion of CD4+ T cells in adult mice prevented HBsAg seroclearance and hepatocellular injury and disrupted hepatic leukocyte organization and HBV-specific CD8+ T cell cytotoxicity, whereas depletion of CD8+ T cells did not alter HBsAg seroclearance. Upstream of the CD4+ T cell response, hepatic myeloid cells, particularly type 2 conventional dendritic cells, directed CD4+ T cell priming and differentiation. Studies using samples from patients with CHB identified features of HBsAg clearance that overlapped with the mouse model, including T helper 1 and cytotoxic CD4+ T cell activation and augmented CD8+ T cell effector function. These findings identified a role for CD4+ T cell activation in the clinical cure of CHB and suggest that therapeutically enhancing CD4+ T cell responses could improve HBsAg clearance rates.
引用
- Jespersen JM, Avanesyan L, Publicover J, et al. Clinical cure of chronic hepatitis B is associated with priming and perpetuation of hepatic CD4+ T cell responses. Sci Transl Med. 2026. PMID: 42054492. doi:10.1126/scitranslmed.adx1523
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。